Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 205

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Utah’s Quiet Revolution: Why HB 390 May Be the Most Significant Psychedelic Legislation of 2026

MindMed Enrolls First Participant in a Study of its Session Monitoring...

PT285 – Andrew Penn, NP – The Need for Nurses in...

Psychedelic Research Bulletin: December 2021

Nova Mentis Provides Corporate Update – 2022 Planned Catalysts

Filament Health and Cybin Therapeutics Announce Licensing Agreement

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Psychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule...

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary...

PharmaDrug Announces Resignation of Director

PT284 – Jonathan Sabbagh – Ketamine-Assisted Psychotherapy and Collaborative Care

Load more

EDITOR PICKS

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

Psychedelic Policy Briefing: June 11, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©